Kupando receives 13 million euros

The start-up was able to convince Remiges Ventures and High-Tech Gründerfonds, among others, in its Series A financing round.

The biopharma start-up Kupando has raised 13 million euros in its Series A financing round. Venture capitalist Remiges Ventures is leading the round. The co-lead investor is Lifecare Partners, with money also coming from Brandenburg Kapital, High-Tech Gründerfonds, Ventura Biomed Investors and several family offices.

Kupando develops substances that are designed to stimulate innate immunity against cancer and other infectious diseases. The start-up says it has a drug candidate, KUP101, for which it now wants to apply for a clinical trial. "It's really nice that we now have the opportunity to develop compounds that can make a difference in the treatment of solid tumors and the prevention of infectious diseases in terms of efficacy, safety and financial affordability," says Johanna Holldack, CEO of Kupando.

The start-up also receives praise from its main investor. "Kupando is a true pioneer in the development of a novel innate immunity stimulator, and we look forward to working with the team and supporting the progression of KUP101 into clinical development," says Kazuhiko Nonomura of Remiges Ventures.